DW10075
DW10075 is a highly selective and orally active VEGFR inhibitor targeting the VEGF/VEGFR pathway. DW10075 selectively inhibits VEGFR-1, VEGFR-2, and VEGFR-3, but has no effect on FGFR and PDGFR. DW10075 inhibits VEGF-induced HUVEC proliferation, migration, and tube formation. And DW10075 inhibits angiogenesis in both the rat aortic ring model and the chick chorionic membrane model. DW10075 also exhibits antiproliferative activity against human cancer cell lines, with IC50s of 2.2 μM and 22.2 μM against U87-MG human glioblastoma cells and A375 melanoma cells, respectively. In the nude mouse U87-MG xenograft tumor model, DW10075 (po) significantly inhibits tumor growth and reduces the expression of CD31 and Ki67 in tumor tissues.
Product Specifications
CAS Number
1804982-31-7
UNSPSC
12352005
Target
VEGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/dw10075.html
Smiles
O=C(C1=CC=CC2=CC(OC3=NC(NC4=CC=CC(NC(C)=O)=C4)=NC=C3)=CC=C21)NC5=CC=CC=C5
Molecular Formula
C29H23N5O3
Molecular Weight
489.52
References & Citations
[1]DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
APC-Linked Polyclonal Antibody to Glial Fibrillary Acidic Protein (GFAP)
APC-Linked Polyclonal Antibody to Glial Fibrillary Acidic Protein (GFAP)